Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Solid Tumors
Filter by Topic
Bladder Cancer
Breast Cancer
Colon Cancer
Colorectal Cancer
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancer
Head and Neck Cancer
Liver Cancer
Lung Cancer
Melanoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Thyroid Cancer
Phi Index Can Select Patients with Prostate Cancer for Active Surveillance
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
April 2014, Vol 5, No 3
San Francisco, CA—A new tool called the Prostate Health Index (phi) can identify which patients with favorable-risk prostate cancer can safely be managed with active surveillance and which patients will probably require treatment. The
phi
index is relatively low tech and is calculated using 3 serum measurements: prostate-specific antigen (PSA), free/total PSA, and a measurement called [-2]proPSA.
Read Article
14 New Genetic Markers Predict Risk for Prostate Cancer
By
Neil Canavan
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
April 2014, Vol 5, No 3
A mutation in any 1 of a suite of DNA repair pathway genes may predict not only the risk for familial prostate cancer, but also indicate the presence of a particular aggressive form of the disease, according to results of a new UK study from the Institute of Cancer Research in London.
Read Article
Encouraging Long-Term Safety Data for Radium-223
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
March 2014, Vol 5, No 2
Results of a study reported at the 2014 Genitourinary Cancers Symposium showed that at 1.5 years after the last injection of this therapy, minimal myelosuppression and minimal nonhematologic adverse events were reported, and there were no reports of cancers of concern, including acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), and primary bone cancer
Read Article
QOL Improved with 18 versus 36 Months of Hormonal Therapy in Patients with High-Risk Prostate Cancer, Confirming Earlier Efficacy Evidence
By
Alice Goodman
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
March 2014, Vol 5, No 2
San Francisco, CA—Longer-term follow-up of a large randomized phase 3 trial suggests that quality of life (QOL) is improved when patients with high-risk prostate cancer have a shorter versus longer course of androgen- deprivation therapy (ADT) plus radiotherapy as primary treatment. In this follow-up study, 18 months of ADT were found to improve QOL versus 36 months of ADT when added to radiotherapy.
Read Article
Previous Docetaxel Therapy Thwarts Enzalutamide Activity in CRPC
By
Charles Bankhead
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
March 2014, Vol 5, No 2
San Francisco, CA—Men with castration-resistant prostate cancer (CRPC) had inferior time duration to prostate-specific antigen (PSA) progression and of progression-free survival (PFS) if they received the androgen receptor agonist enzalutamide (Xtandi) after the taxane docetaxel (Taxotere) rather than before, according to data from a retrospective study presented at the 2014 Genitourinary Cancers Symposium.
Read Article
Large Study Supports Early Oophorectomy for BRCA Mutation Carriers
By
Alice Goodman
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
March 2014, Vol 5, No 2
Women who carry the
BRCA1
or
BRCA2
mutation had an 80% reduction in risk for ovarian, fallopian tube, or breast cancer if they underwent preventive oophorectomy, according to a large prospective study, and a 77% reduction in all-cause mortality (Finch AP, et al.
J Clin Oncol
. 2014 February 24 [Epub ahead of print]).
Read Article
FDG-PET Helps Predict Prostate Cancer Prognosis
By
Rosemary Frei, MSc
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
October 2013, Vol 4, No 8
Niagara Falls, Ontario—Researchers have determined that 18F-fluorodeoxyglucose (FDG) positron emission tomography (FDG-PET), a widely available and relatively inexpensive imaging modality, could be used to shape treatment plans for patients who have been diagnosed with high Gleason score prostate cancer.
Read Article
Comparative Effectiveness Research Should Reap Benefits for Oncology Care
By
Audrey Andrews
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—Comparative effectiveness research (CER) is an important construct for identifying and summarizing the evidence on the effectiveness, safety, and overall value of alternative strategies in oncology care, said Gary H. Lyman, MD, MPH, Professor of Medicine, Duke University and the Duke Cancer Research Institute, Durham, NC, during the 2013 Breast Cancer Symposium.
Read Article
Current Patterns and Costs of Treating Patients with Metastatic Breast Cancer
By
Audrey Andrews
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—In a population of patients with metastatic breast cancer and Medicare Part D claims, the mean lifetime cost of treatment was approximately $102,000, according to a study presented at the 2013 Breast Cancer Symposium by Hope S. Rugo, MD, Director, Breast Oncology Clinical Trials Program, University of California, San Francisco.
Read Article
Role of Radiation and Imaging in DCIS Explained
By
Phoebe Starr
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—Management of ductal carcinoma in situ (DCIS) was the focus of 2 studies highlighted at a press conference before the 2013 Breast Cancer Symposium.
Read Article
Page 12 of 16
7
8
9
10
11
12
13
14
15
16
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma